AP9901581A0 - Therapeutic combinations for musculoskeletal frailty. - Google Patents

Therapeutic combinations for musculoskeletal frailty.

Info

Publication number
AP9901581A0
AP9901581A0 APAP/P/1999/001581A AP9901581A AP9901581A0 AP 9901581 A0 AP9901581 A0 AP 9901581A0 AP 9901581 A AP9901581 A AP 9901581A AP 9901581 A0 AP9901581 A0 AP 9901581A0
Authority
AP
ARIPO
Prior art keywords
compositions
frailty
pyridin
oxo
phenyl
Prior art date
Application number
APAP/P/1999/001581A
Other languages
English (en)
Inventor
Huazhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP9901581A0 publication Critical patent/AP9901581A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
APAP/P/1999/001581A 1998-06-16 1999-06-10 Therapeutic combinations for musculoskeletal frailty. AP9901581A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
AP9901581A0 true AP9901581A0 (en) 1999-06-30

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001581A AP9901581A0 (en) 1998-06-16 1999-06-10 Therapeutic combinations for musculoskeletal frailty.

Country Status (29)

Country Link
EP (1) EP1085867A1 (is)
JP (1) JP2002518328A (is)
KR (1) KR20010052817A (is)
CN (1) CN1305378A (is)
AP (1) AP9901581A0 (is)
AR (1) AR018868A1 (is)
AU (1) AU3342099A (is)
BG (1) BG105128A (is)
BR (1) BR9911357A (is)
CA (1) CA2335112A1 (is)
CO (1) CO5070586A1 (is)
EA (1) EA200001189A1 (is)
GT (1) GT199900083A (is)
HR (1) HRP20000857A2 (is)
HU (1) HUP0102395A2 (is)
ID (1) ID26726A (is)
IL (1) IL139587A0 (is)
IS (1) IS5727A (is)
MA (1) MA26648A1 (is)
NO (1) NO20006381L (is)
OA (1) OA11569A (is)
PA (1) PA8472101A1 (is)
PE (1) PE20000633A1 (is)
PL (1) PL345064A1 (is)
SK (1) SK18902000A3 (is)
TN (1) TNSN99118A1 (is)
UY (1) UY25557A1 (is)
WO (1) WO1999065488A1 (is)
ZA (1) ZA993973B (is)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
MXPA04005112A (es) * 2001-11-29 2005-04-29 Gtx Inc Prevencion y tratamiento de osteoporosis inducida por privacion de androgeno.
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
SK18902000A3 (sk) 2001-12-03
JP2002518328A (ja) 2002-06-25
BG105128A (en) 2001-11-30
PL345064A1 (en) 2001-11-19
IS5727A (is) 2000-11-24
AU3342099A (en) 2000-01-05
BR9911357A (pt) 2001-03-13
HRP20000857A2 (en) 2001-10-31
ZA993973B (en) 2000-12-15
WO1999065488A1 (en) 1999-12-23
CO5070586A1 (es) 2001-08-28
OA11569A (en) 2004-07-01
CA2335112A1 (en) 1999-12-23
NO20006381D0 (no) 2000-12-14
UY25557A1 (es) 2001-01-31
PA8472101A1 (es) 2000-09-29
HUP0102395A2 (hu) 2001-11-28
KR20010052817A (ko) 2001-06-25
AR018868A1 (es) 2001-12-12
CN1305378A (zh) 2001-07-25
PE20000633A1 (es) 2000-07-26
ID26726A (id) 2001-02-01
GT199900083A (es) 2000-12-05
TNSN99118A1 (fr) 2005-11-10
EP1085867A1 (en) 2001-03-28
NO20006381L (no) 2000-12-14
EA200001189A1 (ru) 2001-06-25
IL139587A0 (en) 2002-02-10
MA26648A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
DK1222195T3 (da) Hidtil ukendte thiazolo[4,5-d]pyrimidinforbindelser
LU91710I2 (fr) Pazopanib, facultativement sous forme d'un sel ou d'un solvate pharmaceutiquement acceptable de celui-ci
SE9702001D0 (sv) Novel compounds
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
NO993027D0 (no) Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
AP9901582A0 (en) Combination therapy for musculoskeletal frailty.
EA200001189A1 (ru) Терапевтические комбинации (избирательных) модуляторов рецепторов эстрогенов (имрэ) и стимуляторов секреции гормона роста (ссгр) для лечения скелетно-мышечной слабости
YU75800A (sh) Terapeutske kombinacije koje sadrže modulator selektivnog estrogen receptora i paratiroidni hormon
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
CA2274381A1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
GB0112494D0 (en) New therapeutic use
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
EP1465616A4 (en) TREATMENT OF SIDE EFFECTS OF STATINE USING URIDINE DERIVATIVES
HK1062268A (en) Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration